Specific sites in the linker region of human P-glycoprotein of 2.6 + 0.2 mol of phosphate/mol of peptide. Ser-667, Ser-671 phosphorylated by protein kinase C (PKC) were identified by and Ser-683 were phosphorylated by PKA. Truncated peptides means of a synthetic peptide substrate, PG-2, corresponding to of PG-2 were utilized to confirm that Ser-661 was PKC-specific residues 656-689 from this region of the molecule. As PG-2 has and Ser-683 was PKA-specific. Further studies showed that several sequences of the type recognized by the cyclic AMP-PG-2 acted as a competitive substrate for the P-glycoprotein dependent protein kinase (PKA), PG-2 was also tested as a kinase present in membranes from multidrug-resistant human substrate for PKA. PG-2 was phosphorylated by purified PKC in KB cells. The membrane kinase phosphorylated PG-2 mainly on a Ca2+/phospholipid-dependent manner, with a Km of 1.3 ,M, Ser-661, Ser-667 and Ser-671. These results show that human Pand to a maximum stoichiometry of 2.9 + 0
INTRODUCTION
addition, Pgp can be phosphorylated in vitro by protein kinases other than PKC, including the cyclic AMP-dependent protein A major limiting factor in the effectiveness of cancer chemokinase (PKA) [16] and an incompletely characterized Ca2+-therapy is acquired or intrinsic multidrug resistance (MDR).
independent phospholipid-dependent protein kinase [17] . ThereCross-resistance to anticancer drugs such as the vinca alkaloids, fore the possibility exists for the phosphorylation of Pgp by more anthracyclines and epipodophyllotoxins is due to overexpression than one kinase activated by different signal-transduction of a membrane glycoprotein, P-glycoprotein (Pgp), an energymechanisms. dependent drug-efflux pump [1, 2] . Sequence and hydropathy
Studies of drug accumulation in MDR cells in response to analyses predict Pgp to form two homologous halves with each agents that increase or decrease Pgp phosphorylation have half containing one nucleotide-binding domain and six transconsistently found an inverse relationship between the amount of membrane domains [3, 4] . Although modifications to some drug accumulated and the extent of Pgp phosphorylation features of this model have been proposed [5, 6] , this membrane [12] [13] [14] [15] [18] [19] [20] . These findings suggest a stimulatory role for topology places Pgp in the ATP-binding cassette (ABC) superphosphorylation in Pgp-mediated drug transport. In order to family of active transporters [7] . Another member of this class of understand in more depth the role of phosphorylation in Pgp transporters is the cystic fibrosis transmembrane conductance function, it is necessary to identify the number and location in regulator (CFTR), a cyclic AMP-regulated chloride ion channel the primary sequence of the phosphorylated residues. Recently, [8] .
we have shown that PKC phosphorylates Pgp at multiple sites in An understanding of Pgp structure, function and regulation is the linker region between the two halves of the molecule [21] . central to defining strategies for Pgp inhibition and reversal of This phosphorylated region, which also contains consensus PKA MDR. One potential regulatory mechanism is covalent modisites, may represent a regulatory domain, perhaps analogous to fication by phosphorylation, a universal feature of Pgps expressed the R-domain of CFTR, a target of multisite regulatory in MDR cell lines (e.g. [9] [10] [11] [12] ). Our studies with human epiphosphorylation by PKA and PKC (e.g. [22] [23] , bovine brain PKA holoenzyme [24] and bovine heart PKA catalytic subunit [25] were prepared as described in the references cited.
Peptide synthesis
The sequence of the synthetic peptide PG-2 (see Figure 1 ) was based on the published sequence of residues 656-689 of human MDR I Pgp deduced from the cDNA sequence [4] . Truncated peptides, Pgp-(656-666) and Pgp-(679-687), with the residues indicated in parentheses, were also prepared. The peptides were synthesized by the solid-phase method in an Applied Biosystems (Foster City, CA, U.S.A.) model 430A peptide synthesizer using the t-butyloxycarbonyl/benzyl protecting group strategy, as described elsewhere [26] . The peptides were purified by reversedphase h.p. 30 'C, reaction mixtures were divided and one-half was analysed by SDS/PAGE using 6 % gels [29] and the other half peptide by PAGE using 16.5 % gels [30] .
Other methods Two-dimensional cellulose thin-layer tryptic phosphopeptide mapping was performed as described previously [15] . Tryptic phosphopeptides of PG-2 phosphorylated by PKC or PKA were obtained as described above. Tryptic phosphopeptides of Pgp and PG-2 phosphorylated by the membrane kinase were obtained by excising the protein band from the appropriate gel, and processing the sample as detailed previously [15] . The phospho-(Sigma III-S) and a synthetic peptide substrate derived from peptides were separated in the first dimension by electrophoresis toward the cathode for 3 h at 450 V in a solvent system of pyridine/acetic acid/water (1:10:89, by vol., pH 3.7). Seconddimension ascending chromatography was performed in a solvent system of butan-l-ol/pyridine/acetic acid/water (50:33:1:40, by vol.). Two-dimensional phosphoamino acid analysis was performed as described [21] . Protein concentration was determined with BSA as a standard as described [31] .
RESULTS
Kinetics and stoichlometry of phosphorylation of PG-2 by PKC and PKA
The amino acid sequence of PG-2 is shown in Figure 1 . The peptide was found to be an excellent PKC substrate, with a Vmax value greater than, and a Km value similar to, those for histone HI and TnI-(134-154) ( Table 1 ). Among these PKC substrates, PG-2 was the most effective, as judged by the highest Vmax to Km ratio, ranking PG-2 as one of the best peptide substrates of PKC documented to date [32] . PG-2 was also found to be an effective substrate for PKA, with a Vmax. to Km ratio about 60 % that of histone HI (Table 1) . Similar results were obtained if the free catalytic subunit was used in place of PKA holoenzyme plus cyclic AMP.
The time course and stoichiometry of phosphorylation of PG-2 by PKC or PKA were examined and compared ( Figure 2 ). Phosphorylation by PKC was complete within 3 h and reached a maximum of 2.9+0.1 mol of phosphate/mol of peptide (n = 4). Supplementing the reaction with additional enzyme and ATP at 3 h and incubating for a further 2 h did not increase the phosphorylation stoichiometry (Figure 2 ). Phosphorylation by PKA followed a similar time course, was complete within 2-3 h, reached a maximum of2.6 + 0.2 mol ofphosphate/mol ofpeptide (n = 3), and similarly was not further increased with supplementary enzyme and ATP. Thus phosphorylation stoichiometry was not limited by kinase inactivation or ATP depletion. Phosphorylation of PG-2 by PKC or PKA was dependent respectively on the presence of Ca2+/PS or cyclic AMP; in their absence, phosphate incorporation was less than 0.1 mol/mol (Figure 2 ). phosphorylated by PKA also resolved three major phosphopeptides (spots 1, 2 and 3) and one minor phosphopeptide. The map patterns are consistent with the phosphorylation stoichiometry and suggest that each major phosphopeptide contains one phosphorylation site. Phosphorylation of PG-2 by both kinases resulted in the appearance of all four tryptic phosphopeptides. It is evident that phosphopeptides 1 and 2 are common to both kinases, phosphopeptide 4 is PKC-specific, and phosphopeptide 3 is PKA-specific.
Determination of phosphorylation sites
To determine the serine residues phosphorylated, PG-2 was maximally phosphorylated by PKC or PKA, digested with trypsin, and the digests were subjected to RP-h.p.l.c. (Figure 4 ). The absorbance profile demonstrated an excellent separation of the expected small number of tryptic fragments. In PG-2 phosphorylated by PKC, 32P radioactivity was associated with peptide 1 (unbound), peptide 2 (unbound, retarded) and peptide 4 (eluted at 11-12% acetonitrile). In PG-2 phosphorylated by PKA, 32P radioactivity was associated with peptide 1, peptide 2 and peptide 3 (eluted at 8-9 % acetonitrile). The peak numbers correspond to the numbered phosphopeptides of Figure 3 , as determined by phosphopeptide maps of the individual peaks (results not shown). The four peaks of Figure 4 were subjected to amino acid sequence analysis ( Table 2) . Comparison of the sequences obtained with that of PG-2, together with quantification of both Ser and Ser* (derived mainly from phosphoserine, see the Materials and methods section), allowed identification of the phosphorylated residue in each peptide. Thus PKC phosphorylated Ser-661, Ser-667 and Ser-671, and PKA phosphorylated Ser-667, Ser-671 and Ser-683. With the exception of peptide 3, the sequences obtained are those of limit tryptic peptides of PG-2. The presence of a lysine residue at the N-terminus of peptide 3 is presumably due to preferential trypsin cleavage at the adjacent arginine (see Figure 1) . The minor PKA phosphopeptide evident in the phosphopeptide map (Figure 3) Ser-671
Ser-683 PG-2 ( Figure 4 ) may represent LSTK, the limit tryptic phosphopeptide of Ser-683. These results indicate that PKC and PKA phosphorylated two sites in common and one unique site each. To test further PKC-specific phosphorylation' of Ser-661 and PKA-specific phosphorylation of Ser-683, truncated peptides with sequences surrounding each site were prepared. Pgp-(656-666), with the sequence NDSRSS*LIRKR containing Ser-661 (asterisk), was found to be an effective PKC substrate, as reported earlier [21] . However, the peptide was found to be inactive as a substrate for PKA (Table 1) . On the other hand, the peptide Pgp-(679-687), with the sequence DRKLSTKEA containing Ser-683, was phosphorylated by PKA but was ineffective as a PKC substrate (Table 1) .
PG-2 as a competitive substrate of the Pgp membrane kinase We have previously shown that when Pgp-containing membrane vesicles from MDR KB-V1 cells were incubated under in vitro phosphorylation conditions, Pgp was phosphorylated by endogenous kinase activity [13] . This kinase has not been completely characterized but exhibited the properties of constitutively activated membrane-inserted PKC [13] . It was of interest to determine if the membrane kinase phosphorylated PG-2, and to identify the sites, and therefore membrane phosphorylation reactions were conducted in the absence and presence of the peptide ( Figure 5 ). We found that PG-2 acted as a competitive substrate and, when present in molar excess over Pgp, it completely and specifically inhibited Pgp phosphorylation. Phosphopeptide mapping revealed that incorporation of Figure 5 InhlbitIon by PG-2 of Pgp phosphorylatlot In membranes (a) KB-V1 membrane vesicles (100 4eg, containing approx. 20 pmol of Pgp, based on a molecular mass of 150 kDa and assuming Pgp represents 3% of total membrane protein) were incubated under phosphorylation conditions in the absence (-) or presence (+) of 2 nmol of PG-2. Phosphorylation of Pgp (150 kDa) and PG-2 (4 kDa) was visualized respectively by autoradiography after electrophoresis on 8% or 16.5% gels. (b) Autoradiographs of tryptic phosphopeptide maps of Pgp and PG-2 phosphIrylated by the membrane-associated kinase. The phosphorytated samples were excised from the gels shown in (a) and processed for trypsin digestion and phosphopeptide mapping, as described ir the Materials and methods section. 
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purification and reconstitution of Pgp [33] . Secondly, Pgp is highly phoshorylated in intact cells [9] [10] [11] [12] [13] , and the isolated protein most likely contains significant levels of endogenous phosphate. The presence of endogenous phosphate may in part explain the relatively low stoichiometry of 0.6-1.0 mol of phosphate/mol of Pgp observed for PKC-catalysed in vitro phosphorylation [13, 21] . Finally, synthetic peptides have a proven record of utility in protein kinase research because of their purity, stability, availability in large amounts, and most importantly because protein kinases recognize the local structure around a phosphorylation site [34, 35] . Our synthesis and study ofPG-2 has led to the determination ofthe kinetics, stoichiometry and specific sites of phosphorylation in the linker region of human Pgp catalysed by PKC and PKA. We have found that these protein kinases phosphorylate two sites in common and one unique site each; PKC phosphorylated Ser-661, Ser-667 and Ser-671 and PKA phosphorylated Ser-667, Ser-671 and Ser-683. The sequences surrounding these sites conform well with recognized consensus sequences for these kinases [34, 35] . Ser-661 (RSSLIR), Ser-667 (KRSTRR) and Ser-671 (RRSVR) fit the preference of PKC for neighbouring basic residues on both the N-and C-terminal sides of the phosphorylated residue. However, this is true also for Ser-683 (KLSTK), which was not modified by PKC, emphasizing the importance of additional specificity determinants in site recognition. Likewise, the sequences adjacent to the PKA sites Ser-667 (RKRS), Ser-671 (RRS) and Ser-683 (RKLS) conform to the PKA preference for multiple basic residues on the N-terminal side of the phosphorylated residue.
-Ser-675 (RGS) was not modified by either kinase. The majority of the PKC and PKA sites in various substrate proteins are serine residues, although threonines have been identified in some cases [34] . On the basis of consensus sequence motifs, Thr-668
(KRSTRR) and Thr-684 (RKLSTK) are potential sites for phosphorylation in PG-2, but neither residue was modified by the kinases tested. Experiments with truncated peptides confirmed that Ser-661 was phosphorylated by PKC and not PKA, and the converse was true for Ser-683. These peptides have .potential as selective substrates for the two protein kinases. The electrophoretic and chromatographic properties of the three tryptic phosphopeptides of PG-2 phosphorylated by PKC - Figures 3 and 4) correspond to those of Pgp phosphorylated by PKC documented previously [21] . The PKC sites in Pgp thus appear to be confined to the region of the molecule represented by PG-2. The phosphopeptide maps of Pgp isolated from 32P_ labelled KB-V1 cells also showed a similar pattern of three major phosphopeptides [15] , and in the present study the same map pattern was observed for Pgp phosphorylated by endogenous membrane kinase activity ( Figure 5 ). These observations provide additional evidence that the major Pgp kinase has the sitespecificity characteristics of PKC, and that phosphorylation of this large molecule involves a small cluster of serine residues. We did not observe phosphopeptide 3, the PKA-specific Ser-683 site, in the in vivo phosphopeptide maps [15] . Although this site may not be modified in unstimulated KB-VI cells, it remains to be established whether phosphorylation of Ser-683 occurs in response to agents that activate PKA, e.g. dibutyryl cyclic AMP or forskolin. To our knowledge, the effect of these agents on Pgp phosphorylation in intact MDR cells has not been reported, and thus a physiological role for PKA in Pgp phosphorylation remains unclear. Nonetheless, our studies with PG-2 clearly indicate the presence of specific sites for PKA, and thus the potential exists for phosphorylation of Pgp and modification of function through a cyclic AMP-regulated pathway.
The linker regions of Pgps from different species are, overall, less well conserved than the transmembrane domains and ATPbinding domains [36] . However, the portion of the linker region corresponding to PG-2 in human Pgp is highly conserved in mouse mdr 3 [37] and hamster pgp 1 [38] , rodent homologues of human MDR 1. Like human Pgp, these rodent Pgps contain multiple PKC/PKA consensus phosphorylation sites in this region. In fact, the sequence around the PKA-specific site Ser-683, QDRKLSTKEALD (Figure 1) , is perfectly conserved, and the sequence encompassing the three PKC serines is nearly so. The corresponding region in mouse mdr I is less conserved [3] , although at least one PKC site and one PKA site are present which correspond respectively to Ser-667 and Ser-683 in human MDR I (G. Orr and S. B. Horwitz, personal communication). This evolutionary conservation of multiple phosphorylation sites in the linker regions of these drug-transporting Pgp members suggests an important role for this domain in Pgp function. However, it remains to be established to what extent phosphorylation influences Pgp structure and function. Phosphorylation could induce conformational alterations within the Pgp molecule, influence the stability of oligomeric structures, for which evidence exists [39] , regulate Pgp ATPase activity, alter the drug-binding affinity, or modify an as yet uncovered property of the transporter. Many of these possibilities can be tested with mutants lacking the phosphorylation sites that have now been identified.
